Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated)

被引:1
|
作者
Michalska-Krzanowska, Grazyna
Czuprynska, Maria
机构
[1] Clin Hosp 2, Dept Anaesthesiol & Intens Care, PL-70111 Szczecin, Poland
[2] M Curie Hosp, Dept Anaesthesiol & Intens Care, Szczecin, Poland
关键词
activated protein C; recombinant factor Vlla; septic shock; sepsis;
D O I
10.1159/000093643
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report on 2 cases of severe sepsis treated with drotrecogin-alpha (Xigris, Eli Lilly), where massive perioperative haemorrhage required administration of recombinant factor Vila. The first patient developed severe sepsis after surgery (laparoscopic cholecystectomy, laparotomy due to peritonitis). After 18 h of treatment with Xigris, the patient developed massive, refractory gastrointestinal and abdominal bleeding. Effective haemostasis was achieved after 2 doses of NovoSeven (Novo Nordisk, Denmark). The patient died due to a cerebral bleed. The second patient developed septic shock in the course of pyelonephritis and right hydronephrosis. She was treated with Xigris and nephrectomy. Uncontrollable perioperative bleeding was effectively treated with 2 doses of NovoSeven. The patient survived. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:126 / 130
页数:5
相关论文
共 50 条
  • [41] Use of recombinant activated factor VII in patients with severe coagulopathy and bleeding
    Ho, AMH
    Dion, PW
    Karmakar, MK
    ANESTHESIOLOGY, 2003, 98 (04) : 1025 - 1026
  • [42] Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
    Thomas Klitgaard
    Rene Tabanera y Palacios
    Kenneth D Boffard
    Philip TC Iau
    Brian Warren
    Sandro Rizoli
    Rolf Rossaint
    Yoram Kluger
    Bruno Riou
    Critical Care, 10
  • [43] Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
    Klitgaard, Thomas
    Palacios, Rene Tabanera y
    Boffard, Kenneth D.
    Lau, Philip T. C.
    Warren, Brian
    Rizoli, Sandro
    Rossaint, Rolf
    Kluger, Yoram
    Riou, Bruno
    CRITICAL CARE, 2006, 10 (04):
  • [44] Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia
    Wrobel, Grazyna
    Dobaczewski, Grzegorz
    Patkowski, Dariusz
    Sokol, Agnieszka
    Grotthus, Elibieta
    PEDIATRIC BLOOD & CANCER, 2006, 47 (05) : 729 - 730
  • [45] Clinical experience with recombinant activated factor VII for severe intractable bleeding
    Oliveri, CV
    Manale, SB
    Han, MC
    Stubbs, JR
    TRANSFUSION, 2003, 43 (09) : 4A - 5A
  • [46] Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia
    Ansari, Amir M.
    Khorasanchi, Adam
    Faghihimehr, Armaghan
    Toor, Amir
    CLINICAL CASE REPORTS, 2021, 9 (10):
  • [47] Recombinant activated factor VII to control life-threatening haemorrhagic radiation cystitis
    S. S. Connolly
    F. T. D’Arcy
    M. O. Corcoran
    Irish Journal of Medical Science, 2010, 179 : 431 - 433
  • [48] Recombinant activated factor VII to control life-threatening haemorrhagic radiation cystitis
    Connolly, S. S.
    D'Arcy, F. T.
    Corcoran, M. O.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2010, 179 (03) : 431 - 433
  • [49] Management and monitoring of recombinant activated factor VII
    Ingerslev, J
    Christiansen, K
    Calatzis, A
    Holm, M
    Ebbesen, LS
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 : S25 - S30
  • [50] Activated recombinant factor VII in cardiac surgery
    Steiner, Marie E.
    Key, Nigel S.
    Levy, Jerrold H.
    CURRENT OPINION IN ANESTHESIOLOGY, 2005, 18 (01) : 89 - 92